
    
      Three studies comprise this program. Study LOV111859/OM5 (double-blind study) was followed by
      two open label extensions - LOV111860/OM5X (1st open label extension - 8 weeks) and
      LOV111821/OM5XX (2nd open label extension - 24 months).

      Studies LOV111859/OM5 and LOV111860/OM5X are outlined in NCT00246636.
    
  